ReviewNaunyn-Schmiedeberg's archives of pharmacology2026
The interplay between vitamin D3 and Nrf2 signaling: mechanistic insights and therapeutic potentials.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress plays a central role in the initiation and progression of numerous pathological conditions, including neurodegenerative, cardiovascular, metabolic, hepatic, and inflammatory disorders. The nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway is recognized as a master regulator of cellular antioxidant defense, mediating the transcription of a wide array of antioxidant and cytoprotective genes. Beyond its classical role in calcium and bone homeostasis, vitamin D3 (VitD3) exerts a broad spectrum of non-classical biological effects. Accumulating evidence highlights its anti-inflammatory, anti-oxidative, anti-angiogenic, and anti-cancer properties, while VitD3 deficiency has been implicated in the pathogenesis of various cardiovascular, inflammatory, and malignant diseases. Among these emerging non-calcemic functions, the antioxidant capacity of VitD3 has gained increasing attention. Recent studies suggest that calcitriol, the active form of VitD3, may modulate the Nrf2 signaling pathway and its downstream protective responses. This review synthesizes current evidence on the potential role of VitD3-mediated Nrf2 modulation across diverse disease models. Collectively, targeting the VitD3-Nrf2 axis may represent a promising mechanistic target for future therapeutic investigation.
Indexed as
Identifiers
42828539What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.